

Reading List Edwards Alzheimer's disease

Edwards Lab Refs

Wood et al., (2022) Upregulation of Trem2 expression occurs exclusively on microglial contact with plaques. BioRXiv doi:10.1101/2022.01.26.477873 [Spatial cell-type enriched transcriptomics] Benitez, D. et al., (2021) Knock-in models related to Alzheimer's disease: synaptic transmission, plaques and the role of microglia. Molecular Neurodegeneration 16, 47 [APPKI mouse comparison] Liu, W. et al. (2020) Trem2 promotes anti-inflammatory responses in microglia and is suppressed under pro-inflammatory conditions. Human Molec Gen. 29, 3224-3248 [Trem2] Edwards, F.A. (2019) A Unifying Hypothesis for Alzheimer's Disease: From Plaques to Neurodegeneration. Trends Neurosci 42 (5), 310-322. [Hypothesis] Joel, Z. et al. (2018) Improving Mouse Models for Dementia. Are All the Effects in Tau Mouse Models Due to Overexpression? Cold Spring Harb Symp Quant Biol 83, 151-161.[overexpression of Tau and early APPKI results] Cummings, D.M. et al. (2015) First effects of rising amyloid-beta in transgenic mouse brain:

Cummings, D.M. et al. (2015) First effects of rising amyloid-beta in transgenic mouse brain: synaptic transmission and gene expression. Brain 138 (Pt 7), 1992-2004.[first effects of Aβ] Matarin, M., A (2015) Genome-wide Gene-Expression Analysis and Database in Transgenic Mice during Development of Amyloid or Tau Pathology. Cell Reports 10, 633–644 [Microglial gene expression; correlation with plaque load in transgenic mice]

APPKI mice

Saito, T. et al. (2014) Single App knock-in mouse models of Alzheimer's disease. Nat Neurosci 17 (5), 661-3

Trem2 GWAS

Guerreiro, R. and Hardy, J. (2013) TREM2 and neurodegenerative disease. N Engl J Med 369 (16), 1569-70.

Preclinical biomarkers

Mila-Aloma et al., (2020) Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum. Alzheimer's & Dementia doi: 10.1002/alz.12131

Review about risk factors

Hardy, J. and Escott-Price, V. (2019) Genes, pathways and risk prediction in Alzheimer's disease. Hum Mol Genet 28 (R2), R235-R240.

Reviews/perspectives about therapeutics and diagnosis

Karran, E. and De Strooper, B. (2022) The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov 21, 306-318 Scheltens et al., (2021) Alzheimer's disease Lancet 397, 1577–1590

Useful websites

www.alzforum.org Informative website with recent refs and commentaries from experts

<u>www.alzheimers.org.uk</u> Alzheimer's Society with lots of useful background information for researchers or community about the disease

Frances Edwards, PhD Professor of Neurodegeneration UCL DEPARTMENT OF NEUROSCIENCE PHYSIOLOGY & PHARMACOLOGY University College London Gower Street London WC1E 6BT Tel: +44 (0)20 7679 3286; Mob: +447528593488 f.a.edwards@ucl.ac.uk